Vivoryon Therapeutics N.V. (AMS:VVY)

Market Cap	42.05M -19.7%
Revenue (ttm)	n/a
Net Income	-12.48M
EPS	-0.48
Shares Out	29.61M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	27,963
Average Volume	36,601
Open	1.460
Previous Close	1.456
Day's Range	1.420 - 1.460
52-Week Range	1.352 - 2.020
Beta	1.57
RSI	45.61
Earnings Date	Apr 24, 2026

About Vivoryon Therapeutics

Vivoryon Therapeutics N.V. operates as a clinical stage biopharmaceutical company that focuses on research, development, and commercialize small molecule-based medicines. Its pipeline products target toxic pyroglutamate-Abeta (pGlu-Abeta), which inhibits the production of pGlu-Abeta. The company’s lead product candidate is PQ912, a nanomolar QPCT inhibitor that has completed Phase IIb clinical trials for use in the treatment of Alzheimer’s disease. In addition, the company is developing a monoclonal antibody PBD-C06 is for N3pE-Abeta. Vivoryon ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1997
• Employees: 14
• Stock Exchange: Euronext Amsterdam
• Ticker Symbol: VVY